Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and...
Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Remdesivir is an RNA polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 administered intravenously (IV) that is approved for the treatment of coronavirus disease 2019 in hospitalized and nonhospitalized patients. The clinical dosing regimen is a single loading dose of 200 mg on Day 1 followed by once‐daily maintenan...
Alternative Titles
Full title
Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ca669b9317f240afa0b269ae01cb67ba
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ca669b9317f240afa0b269ae01cb67ba
Other Identifiers
ISSN
1752-8054,1752-8062
E-ISSN
1752-8062
DOI
10.1111/cts.70159
